A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes

"2 periods of 12 weeks of once weekly dosing with multiple doses of semaglutide, for subcutaneous (s.c., under the skin) injection, escalated up to 1.0 mg semaglutide.~Each treatment period will be followed by a hypoglycaemic clamp"

"2 periods of 12 weeks of once weekly dosing, subcutaneous (s.c., under the skin) injection.~Each treatment period will be followed by a hypoglycaemic clamp."